Viewing nowCombinationJanumet 50/1000 mg Tablets
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.

MFDS item code 200713009 · Approved 2007.12.04 · Insurance code 643309610
Improvement of glycemic control in patients with type 2 diabetes mellitus
This drug is used for improving blood sugar control in patients with type 2 diabetes by assisting dietary and exercise therapy, with the combination of sitagliptin and metformin.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic medication whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined taking the patient's blood glucose level and existing dose into account. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This drug contains the ingredients sitagliptin and metformin and is used in the treatment of diabetes. First, this drug may cause serious allergic reactions, although rare; therefore, if symptoms such as rash, hives, or difficulty breathing occur, discontinue use immediately and consult a doctor. Additionally, there is a risk of acute pancreatitis, which is inflammation of the pancreas, so if severe abdominal pain, vomiting, or nausea occurs, seek immediate medical attention. This drug should not be administered to patients with impaired kidney function, particularly those with moderate or severe renal impairment, and regular kidney function tests should be conducted. Especially in cases of dehydration, severe infection, heart failure, or acute myocardial infarction, this drug should not be administered or should be temporarily suspended. Patients scheduled for surgery should stop taking this drug 48 hours prior to the procedure and can resume again after kidney function has returned to normal post-surgery. It is safer for women who are pregnant or may become pregnant, as well as breastfeeding mothers, to avoid taking this drug. Pay attention to symptoms of hypoglycemia during treatment, especially when used in combination with other hypoglycemic agents or insulin, as the risk of hypoglycemia may increase. During treatment, ensure that meal patterns are not irregular or insufficient, and proper nutritional supplementation is necessary after intense exercise. This drug has an increased risk of lactic acidosis when taken with alcohol; therefore, it is advisable to avoid drinking. Also, this drug may interact with certain medications, so if other drugs are being taken, it is essential to inform the doctor or pharmacist. Regular blood tests and kidney function tests should be performed to confirm the safety of the medication, and monitoring of vitamin B12 levels is also recommended. If blisters on the skin or severe joint pain occur while taking this drug, consult a doctor immediately. Finally, this drug is not recommended for use in children under 18 years of age, as safety and efficacy have not been established.
Not everyone experiences these, and they can vary from person to person.
Store this drug in a tightly closed container to prevent air or moisture from entering. The storage temperature should be kept between 1 to 30 degrees Celsius, preferably at room temperature.
Oval film-coated tablet, red in color, engraved with 577 on one side.
56 tablets (14 tablets/ PTP x 4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.